More about
Exon
Clinical Guidance
Non-Small Cell Lung Cancer
Treatment Options
Precision and Immune-Based Therapies
News
December 21, 2023
1 min read
Save
Positive data in study of drug for Duchenne muscular dystrophy with exon 44 skipping
Avidity Biosciences Inc. has announced positive data in healthy volunteers from its ongoing phase 1/2 clinical trial of a proprietary monoclonal antibody to treat Duchenne muscular dystrophy mutations amenable to exon 44 skipping.
News
April 28, 2023
1 min read
Save
FDA grants fast track designation to exon-skipping Duchenne muscular dystrophy therapy
The FDA has granted fast track designation to AOC 1044 for the treatment of Duchenne muscular dystrophy in people with mutations amenable to exon 44 skipping, Avidity Biosciences announced in a press release.